Executive Vice President, Chief Financial Officer and Chief Business Officer
"The trajectory of Sarepta’s success has been built on three fundamental principles: do what’s best for the patient; grow aggressively, but prudently; and attract the right people who are driven to execute today, but who are also able to look around the corner for tomorrow’s opportunities."
As Executive Vice President, Chief Financial Officer, and Chief Business officer, Sandy Mahatme leads finance, business development, investor and public relations, facilities and information technology (IT). He joined Sarepta in 2012 to help the Company realize its goal of bringing life-saving therapies to people in need.
“I came here because I saw Sarepta as a chance to transform healthcare—to actually transform peoples’ lives. And I felt I could help grow the Company. The trajectory of Sarepta’s success has been built on three fundamental principles: do what’s best for the patient; grow aggressively, but prudently; and attract the right people who are driven to execute today, but who are also able to look around the corner for tomorrow’s opportunities.”
Since joining Sarepta, Sandy has helped the Company raise over $2.5 billion via financings and highly valuable business development deals. As a result, Sarepta’s portfolio has deepened, and its infrastructure has been greatly strengthened. Since 2012, Sarepta has grown dramatically – its employee base has expanded from around 100 to over 700 employees (as of November 2019), its pipeline from nine to over 40 programs in various stages of development, and its footprint of a single location in Cambridge, Massachusetts to over a dozen locations across the U.S. and around the world. Further, Sandy was instrumental in leading the Company’s numerous strategic manufacturing deals, building capacity from the ground up and securing Sarepta’s position as the leader in gene therapy and RNA manufacturing.
Sandy joined Sarepta from Celgene Corporation. As a Senior Vice President at Celgene, he established Celgene’s corporate development function, focusing on emerging markets, acquisitions, and global manufacturing. Prior to Celgene, he served in increasingly senior roles at Pfizer in business development and tax. He began his career at Ernst & Young, advising multi-national corporations.
Sandy holds Master of Laws degrees from Cornell University and New York University, and is a member of the New York State Bar. He serves on the Board of Directors for Flexion Therapeutics, Inc. and Aeglea BioTherapeutics, Inc.